Tricida Stock Price, Forecast & Analysis (NASDAQ:TCDA)

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida Inc (NASDAQ:TCDA) issued its earnings results on Thursday, August, 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.12. View Tricida's Earnings History.

Tricida is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Tricida.

Tricida will be holding an earnings conference call on Thursday, November 14th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

3 equities research analysts have issued twelve-month price objectives for Tricida's shares. Their forecasts range from $48.00 to $58.00. On average, they anticipate Tricida's share price to reach $51.50 in the next year. This suggests a possible upside of 31.9% from the stock's current price. View Analyst Price Targets for Tricida.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tricida.

Media stories about TCDA stock have trended very negative recently, InfoTrie reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Tricida earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Tricida.

Tricida saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 3,390,000 shares, a decrease of 5.0% from the September 30th total of 3,570,000 shares. Based on an average trading volume of 198,500 shares, the short-interest ratio is presently 17.1 days. Approximately 9.8% of the company's shares are sold short. View Tricida's Current Options Chain.

Some companies that are related to Tricida include Ionis Pharmaceuticals (IONS), SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Reata Pharmaceuticals (RETA), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), The Medicines (MDCO), GW Pharmaceuticals PLC- (GWPH) and United Therapeutics (UTHR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), The Medicines (MDCO), Ocular Therapeutix (OCUL), SAGE Therapeutics (SAGE), Affimed (AFMD), Amarin (AMRN) and Arena Pharmaceuticals (ARNA).

(TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

Tricida's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (0.64%), California Public Employees Retirement System (0.09%), Rhumbline Advisers (0.06%), Nisa Investment Advisors LLC (0.01%), Tower Research Capital LLC TRC (0.00%) and Zurcher Kantonalbank Zurich Cantonalbank (0.00%). Company insiders that own Tricida stock include Beek Jeroen B Van, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Steffen Pietzke and Wilhelm Stahl. View Institutional Ownership Trends for Tricida.

TCDA stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA and Rhumbline Advisers. Company insiders that have sold Tricida company stock in the last year include Claire Lockey, Dawn Parsell Otto, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal and Wilhelm Stahl. View Insider Buying and Selling for Tricida.

TCDA stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Nisa Investment Advisors LLC, Tower Research Capital LLC TRC and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $39.04.

Tricida has a market capitalization of $1.93 billion. The company earns $-102,810,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Tricida employs 76 workers across the globe.View Additional Information About Tricida.

The official website for Tricida is http://www.tricida.com/.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]